skip to content
Home

EPSRC IRC in Targeted Delivery for Hard-to-Treat Cancers

 

News Subscribe to News

Read more at: Study using drug-loaded hydrogels with mechanical properties matched to brain tissue for drug-delivery in human glioblastoma models shows improved survival

Study using drug-loaded hydrogels with mechanical properties matched to brain tissue for drug-delivery in human glioblastoma models shows improved survival

24 November 2021

Glioblastoma (GB) is the most common primary brain cancer in adults and has one of the lowest median survival rates for cancer of just 4.6 months when left untreated. Even patients who meet the criteria to undergo the current standard treatment – surgery to remove the tumour followed by radiotherapy and chemotherapy –...

Read more at: What can we do about difficult cancers?

What can we do about difficult cancers?

15 November 2021

Members of the IRC are taking part in an event at Jesus College discussing how new advances in engineering and chemistry can be used to tackle the most difficult to treat cancers. Titled ‘What can we do about difficult cancers?’, the online and in-person event, on Tuesday 30 November at 7.30pm, brings together a number of...

Read more at: IRC postdoctoral researcher wins award for industrial placement

IRC postdoctoral researcher wins award for industrial placement

5 November 2021

Dr Paraskevi Kasapidou has been awarded a Biotechnology and Biological Sciences Research Council (BBSRC) Flexible Talent Mobility Account award that supports knowledge exchange between industry and academia . The industrial placement will be at Aqdot, a UK based company with expertise in developing, licensing and...

Read more at: Nano-engineering to kill cancer – IRC member is finalist for a prestigious life sciences award

Nano-engineering to kill cancer – IRC member is finalist for a prestigious life sciences award

26 October 2021

IRC member, immunologist Dr Su Metcalfe, has been shortlisted to receive a coveted OBN Award that celebrates the UK Life Sciences industry, including individuals and companies that have made an outstanding impact in their field. Dr Metcalfe is a Senior Research Associate in the Clinical School at the University of...

Read more at: Read the latest Cancer in Sight blog published today

Read the latest Cancer in Sight blog published today

25 October 2021

The latest in the monthly IRC blog series, Cancer in Sight, written by post-graduate Research Associate Dr Paraskevi Kasapidou, reflects on her personal and professional motivation as part of the IRC team developing hydrogels for hard-to-treat cancers. Titled ‘ Understanding the urgency of research in drug delivery for...

Read more at: New inkjet printing could accelerate personalised drug delivery

New inkjet printing could accelerate personalised drug delivery

18 October 2021

A research collaboration with IRC engineers has marked a first by demonstrating the digital inkjet printing and self-organisation of microdroplets on fluid surfaces to create structures of functional materials. The Fluids in Advanced Manufacturing research group, including Dr Qingxin Zhang and the IRC’s Dr Ronan Daly and...

Read more at: Read the latest Cancer in Sight blog published today

Read the latest Cancer in Sight blog published today

24 September 2021

The second in the monthly IRC blog series, Cancer in Sight, considers the benefits and challenges of taking a multi-disciplinary approach to the targeted delivery of drugs for hard-to-treat cancers. This month’s blog, written by Amanda Fuller, IRC Programme Manager, brings focus to the strategically dynamic approach of the...

Read more at: IRC Research Associate wins Rosetrees Enterprise Fellowship Award

IRC Research Associate wins Rosetrees Enterprise Fellowship Award

12 September 2021

Dr Christopher Chapman of Imperial College, London, who is in his third year as a post-doctoral biomedical engineering research associate as part of the IRC team, has been awarded a Rosetrees Enterprise Fellowship. The Rosetrees Enterprise Fellowship is awarded annually and aimed specifically at recently qualified...

Read more at: New IRC co-authored paper now published in ‘Journal for the American Chemical Society’ presents improved shelf-life of Metal-Organic Framework-based drug carriers for better pharmaceutical exploitation

New IRC co-authored paper now published in ‘Journal for the American Chemical Society’ presents improved shelf-life of Metal-Organic Framework-based drug carriers for better pharmaceutical exploitation

2 September 2021

A co-authored paper with contributions from the IRC’s Dr David Fairen-Jimenez and Professor Oren A. Scherman and lead author Dr Xu Chen, Research Associate at the Adsorption and Advanced Materials Lab at the University of Cambridge, has been published in the September issue of the ‘Journal for the American Chemical Society...

Read more at: The IRC launches the Cancer in Sight Blog

The IRC launches the Cancer in Sight Blog

27 August 2021

The Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaboration (IRC) in Targeted Delivery for Hard-to-Treat Cancers is launching a new monthly series of thought-provoking and informative articles – the Cancer in Sight Blog. Written by members of the IRC team, our partners and...

Contact Us

For more information on the EPSRC IRC in targeted delivery for hard-to-treat cancers, please contact the Programme Manager, Claire McGlynn

manager@targeted-delivery.cam.ac.uk

Study at Cambridge

About the University

Research at Cambridge